Thrust Into A New Fundraising Norm
Source: Life Science Leader
By Matthew Pillar, Editor, Bioprocess Online
By the time Randy Schatzman, Ph.D., was the guest on The Business of Biotech podcast, his company, Bolt Biotherapeutics, already had closed a $93 million Series C round of financing in the early months of the COVID pandemic. The CEO had joined Bolt, which focuses on immuno-oncology drug discovery and development, only a year prior.
access the Magazine Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.
Subscribe to Life Science Leader
X
Subscribe to Life Science Leader
This website uses cookies to ensure you get the best experience on our website. Learn more